Patent Summary: "Pyrazol carboxamide derivatives as taar modulators for use in the treatment of various disorders, such as depression, diabetes and parkinson's disease". The present invention relates to compounds of formula I wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, halogen substituted lower alkyl, hydroxy substituted lower alkyl, halogen substituted lower alkoxy or lower alkoxy substituted by hydroxy； or is pyridine-2, 3 or 4-yl optionally substituted by halogen, lower alkyl, lower cycloalkyl, cyano, halogen substituted lower alkyl, hydroxy substituted lower alkyl, lower alkoxy, halogen substituted lower alkoxy or lower alkoxy substituted by hydroxyl； or is pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, hydroxy substituted lower alkyl or halogen substituted lower alkyl； or is pyrazin-2-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, halogen substituted lower alkyl, hydroxy substituted lower alkyl or cyano； or is 2,2-difluorobenzo [d] [1,3] dioxol-5-yl, or is thiazolyl, optionally substituted by halogen-substituted lower alkyl； R2 is hydrogen or lower alkyl； R3 is hydrogen, amino or lower alkyl； z is a bond, -ch2- or -o-； or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas i have a good affinity for the amine associated receptors in traces (taars), especially for taars. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, hyperactivity disorder. Attention Deficit (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological disorders such as parkinson's disease, neurodegenerative disorders such as alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as disorders. eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, energy consumption an
